EMDB/PDB/SASBDBから引用されている文献のデータベース

キーワード
構造解析手法	All X線回折 NMR 電子顕微鏡小角散乱中性子線回折線維回折粉末回折赤外分光 EPR FRET 理論モデルハイブリッド
著者・登録者
ジャーナル
IF	>30 >20 >10 >5 all

タイトル	A humanized yeast proteasome identifies unique binding modes of inhibitors for the immunosubunit beta 5i.
ジャーナル・号・ページ	EMBO J., Vol. 35, Page 2602-2613, Year 2016
掲載日	2016年5月27日 (構造データの登録日)
著者	Huber, E.M. / Heinemeyer, W. / de Bruin, G. / Overkleeft, H.S. / Groll, M.
リンク	EMBO J. / PubMed:27789522
手法	X線回折
解像度	2.4 - 2.9 Å
構造データ	PDB-5l52: Yeast 20S proteasome in complex with epoxyketone inhibitor 14 手法: X-RAY DIFFRACTION / 解像度: 2.7 Å PDB-5l54: Yeast 20S proteasome in complex with epoxyketone inhibitor 16 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-5l55: Yeast 20S proteasome in complex with epoxyketone inhibitor 18 手法: X-RAY DIFFRACTION / 解像度: 2.9 Å PDB-5l5a: Yeast 20S proteasome with human beta5i (1-138; R57T) 手法: X-RAY DIFFRACTION / 解像度: 2.4 Å PDB-5l5b: Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-5l5d: Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with ONX 0914 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-5l5e: Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with carfilzomib 手法: X-RAY DIFFRACTION / 解像度: 2.9 Å PDB-5l5f: Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with bortezomib 手法: X-RAY DIFFRACTION / 解像度: 2.5 Å PDB-5l5h: Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with PR-924 手法: X-RAY DIFFRACTION / 解像度: 2.6 Å PDB-5l5i: Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 9 手法: X-RAY DIFFRACTION / 解像度: 2.9 Å PDB-5l5j: Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 14 手法: X-RAY DIFFRACTION / 解像度: 2.9 Å PDB-5l5o: Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16 手法: X-RAY DIFFRACTION / 解像度: 2.6 Å PDB-5l5p: Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-5l5q: Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone 18 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-5l5r: Yeast 20S proteasome with human beta5i (1-138;V31M) and human beta6 (97-111; 118-133) 手法: X-RAY DIFFRACTION / 解像度: 2.9 Å PDB-5l5s: Yeast 20S proteasome with human beta5i (1-138; V31M) and human beta6 (97-111; 118-133) in complex with PR-924 手法: X-RAY DIFFRACTION / 解像度: 2.6 Å PDB-5l5t: Yeast 20S proteasome with human beta5i (1-138; V31M) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16 手法: X-RAY DIFFRACTION / 解像度: 2.9 Å PDB-5l5u: Yeast 20S proteasome with human beta5i (1-138; V31M) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17 手法: X-RAY DIFFRACTION / 解像度: 2.6 Å PDB-5l5v: 'Yeast 20S proteasome with human beta5i (1-138; V31M) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 18 手法: X-RAY DIFFRACTION / 解像度: 2.7 Å PDB-5l5w: Yeast 20S proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-5l5x: Yeast 20S proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with ONX 0914 手法: X-RAY DIFFRACTION / 解像度: 2.9 Å PDB-5l5y: Yeast 20S proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with carfilzomib 手法: X-RAY DIFFRACTION / 解像度: 2.7 Å PDB-5l5z: Yeast 20S proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with bortezomib 手法: X-RAY DIFFRACTION / 解像度: 2.7 Å PDB-5l60: Yeast 20S proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with PR-924 手法: X-RAY DIFFRACTION / 解像度: 2.7 Å PDB-5l61: Yeast 20S proteasome with human beta5c (1-138) and human beta6 (99-132) in complex with epoxyketone inhibitor 14 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-5l62: Yeast 20S proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-5l63: Yeast 20S proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17 手法: X-RAY DIFFRACTION / 解像度: 2.7 Å PDB-5l64: Yeast 20S proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 18 手法: X-RAY DIFFRACTION / 解像度: 2.7 Å PDB-5l65: Yeast 20S proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with carfilzomib 手法: X-RAY DIFFRACTION / 解像度: 2.9 Å PDB-5l66: Yeast 20S proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with bortezomib 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-5l67: Yeast 20S proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with PR-924 手法: X-RAY DIFFRACTION / 解像度: 2.6 Å PDB-5l68: Yeast 20S proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 14 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-5l69: Yeast 20S proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16 手法: X-RAY DIFFRACTION / 解像度: 2.7 Å PDB-5l6a: Yeast 20S proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-5l6b: Yeast 20S proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with ONX 0914 手法: X-RAY DIFFRACTION / 解像度: 2.6 Å PDB-5l6c: Yeast 20S proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 18 手法: X-RAY DIFFRACTION / 解像度: 2.6 Å PDB-5ltt: Yeast 20S proteasome with human beta5i (1-138; R57T)in complex with PR-924 手法: X-RAY DIFFRACTION / 解像度: 2.7 Å
化合物	ChemComp-MG: Unknown entry / マグネシウムジカチオン ChemComp-CL: Unknown entry / クロリド ChemComp-6N5: ~{N}-[(2~{S})-1-[[(2~{S})-3-(4-methoxyphenyl)-1-[[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]amino]-1-oxidanylidene-propan-2-yl]amino]-1-oxidanylidene-propan-2-yl]-1-methyl-5~{H}-indene-2-carboxamide ChemComp-MES: 2-(N-MORPHOLINO)-ETHANESULFONIC ACID / 2-モルホリノエタンスルホン酸 / pH緩衝剤YM ChemComp-HOH: WATER ChemComp-79P: (2~{S})-3-(1~{H}-indol-3-yl)-~{N}-[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]-2-[[(2~{R})-2-(2-morpholin-4-ylethanoylamino)propanoyl]amino]propanamide ChemComp-6NV: ~{N}-[(2~{R})-1-[[(2~{S})-3-(4-methoxyphenyl)-1-[[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]amino]-1-oxidanylidene-propan-2-yl]amino]-1-oxidanylidene-propan-2-yl]-1-methyl-5~{H}-indene-2-carboxamide ChemComp-04C: 1,2,4-trideoxy-4-methyl-2-{[N-(morpholin-4-ylacetyl)-L-alanyl-O-methyl-L-tyrosyl]amino}-1-phenyl-D-xylitol ChemComp-3BV: N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-[(2R,3S,4S)-1,3-dihydroxy-2,6-dimethylheptan-4-yl]-L-phenylalaninamide / 薬剤, 抗がん剤, 阻害剤YM ChemComp-BO2: N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE / ボルテゾミブ / 薬剤, 抗がん剤YM ChemComp-39V: N-[(3-methyl-1H-inden-2-yl)carbonyl]-D-alanyl-N-[(2S,4R)-5-hydroxy-4-methyl-3-oxo-1-phenylpentan-2-yl]-L-tryptophanamide ChemComp-38X: N-[(3-methyl-1H-inden-2-yl)carbonyl]-D-alanyl-N-[(2S,4R)-1-cyclohexyl-5-hydroxy-4-methyl-3-oxopentan-2-yl]-L-tryptophanamide ChemComp-79L*: (2~{S})-3-(4-methoxyphenyl)-~{N}-[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]-2-[[(2~{R})-2-(2-morpholin-4-ylethanoylamino)propanoyl]amino]propanamide
由来	saccharomyces cerevisiae s288c (パン酵母) saccharomyces cerevisiae (strain atcc 204508 / s288c) (パン酵母) homo sapiens (ヒト) saccharomyces cerevisiae (パン酵母) mus musculus (ハツカネズミ)
キーワード	HYDROLASE/HYDROLASE INHIBITOR / HYDROLASE-HYDROLASE INHIBITOR complex / Proteasome / Inhibitor / Binding Analysis / HYDROLASE complex / Mutant